Your participation will allow you to have firsthand experience with developing new medical treatments that may be beneficial to other patients with shoulder injuries and degenerative conditions. Clinical trial information is excerpted from www.clinicaltrials.gov.
Conventus CAGE™ PH for use in Proximal Humerus Fracture Fixation Doc. Post-Approval Prospective Study
Location: Howard County General Hospital, Johns Hopkins Hospital
Investigators: Uma Srikumaran, M.D., Greg Osgood, M.D., Babar Shafiq, M.D., M.S.
Contact: Sabrina Jenkins; 443-546-1558; firstname.lastname@example.org
The PH Cage device was designed by Conventus Orthopaedics to fix broken shoulders. The PH Cage device is FDA approved and is a permanent implant that holds the broken bones together.
The purpose of this study is to determine:
- Device safety and patient outcome data
- Device usage data
- Performance data for the implant procedure
- Early economic benefit data
- Proximal humerus fracture
- No open wound fractures
- No allergies to nickel/titanium
A Post-Market Clinical Follow-up Study of the TITAN™ Reverse Shoulder System used in Primary or Revision Total Shoulder Arthroplasty
The TITAN™ Reverse Shoulder System (TRS) device is cleared by FDA for the treatment of shoulder diseases requiring shoulder replacement. This research is being done to see how the device does over time and to collect more information about its safety and efficacy.
- Primary or revision total shoulder replacement for shoulder arthritis or fracture
- Grossly deficient rotator cuff
- Functional deltoid muscle
A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® TitanTM Modular Shoulder System 2.5 for Primary Shoulder Joint Replacement
The Titan 2.5 is a FDA approved joint replacement device designed to treat pain, limited motion, or weakness in the shoulder. This research is being done to see how the TITAN™ 2.5 device does over time and to collect more information about its safety and efficacy.
- Osteoarthritis, traumatic/rheumatoid arthritis, fractures or dislocations of shoulder
- Repairable rotator cuff tears
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
This is a research study to test an investigational study drug called FX006. FX006 has previously been FDA approved for the treatment of knee osteoarthritis pain. This research study now aims to see if an injection of FX006 into the shoulder joint can be used to treat patients with shoulder arthritis or frozen shoulder.
Participants in this study will be compensated up to $1100.00 for completion of study diaries and visits.
Study participants will be randomly assigned to receive either the placebo or FX006. They will not know whether they received FX006 or a placebo until the clinical research study is completed.
- Age: 35-80 years
- Shoulder arthritis OR frozen shoulder
- Can only take Tylenol during study for pain control